EA201201529A1 - Комбинация ингибиторов ксантиноксидазы и статинов и ее применение - Google Patents

Комбинация ингибиторов ксантиноксидазы и статинов и ее применение

Info

Publication number
EA201201529A1
EA201201529A1 EA201201529A EA201201529A EA201201529A1 EA 201201529 A1 EA201201529 A1 EA 201201529A1 EA 201201529 A EA201201529 A EA 201201529A EA 201201529 A EA201201529 A EA 201201529A EA 201201529 A1 EA201201529 A1 EA 201201529A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
combination
xanthinoxidase
statins
application
Prior art date
Application number
EA201201529A
Other languages
English (en)
Inventor
Франческо Мелани
Сандро Джульяни
Карло Альберто Маджи
Original Assignee
Менарини Интернешнл Оперейшнз Люксембург С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42753376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201529(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Менарини Интернешнл Оперейшнз Люксембург С.А. filed Critical Менарини Интернешнл Оперейшнз Люксембург С.А.
Publication of EA201201529A1 publication Critical patent/EA201201529A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Изобретение касается комбинации действующих веществ, т.е. ингибитора ксантиноксидазы с одним или более ингибиторами ГМГ-KoA-редуктазы, фармацевтических композиций, содержащих указанные действующие вещества, для применения в терапевтическом лечении людей и животных и способов их получения.
EA201201529A 2010-05-10 2011-05-06 Комбинация ингибиторов ксантиноксидазы и статинов и ее применение EA201201529A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2010A000231A IT1400310B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e statine e loro uso.
PCT/EP2011/057343 WO2011141387A1 (en) 2010-05-10 2011-05-06 Association of xanthine oxidase inhibitors and statins and use thereof

Publications (1)

Publication Number Publication Date
EA201201529A1 true EA201201529A1 (ru) 2013-04-30

Family

ID=42753376

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201529A EA201201529A1 (ru) 2010-05-10 2011-05-06 Комбинация ингибиторов ксантиноксидазы и статинов и ее применение

Country Status (23)

Country Link
US (1) US20130116291A1 (ru)
EP (1) EP2568981A1 (ru)
JP (1) JP2013526499A (ru)
KR (1) KR20130079427A (ru)
CN (1) CN103025329A (ru)
AR (1) AR081375A1 (ru)
AU (1) AU2011252193A1 (ru)
BR (1) BR112012028892A2 (ru)
CA (1) CA2798707A1 (ru)
CL (1) CL2012003033A1 (ru)
CO (1) CO6630144A2 (ru)
CR (1) CR20120618A (ru)
EA (1) EA201201529A1 (ru)
IL (1) IL222926A0 (ru)
IT (1) IT1400310B1 (ru)
MA (1) MA34232B1 (ru)
MX (1) MX2012013052A (ru)
NZ (1) NZ603397A (ru)
PE (1) PE20130811A1 (ru)
SG (1) SG185445A1 (ru)
TW (1) TW201206430A (ru)
WO (1) WO2011141387A1 (ru)
ZA (1) ZA201209294B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112370473A (zh) * 2020-12-04 2021-02-19 首都医科大学附属北京朝阳医院 他汀组合物及其在制备治疗高尿酸血症药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2073981C (en) 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
PL200710B1 (pl) 1998-06-19 2009-01-30 Teijin Pharma Ltd Polimorfy kwasu 2-(3-cyjano-4-izobutyloksyfenylo)-4-metylo-5-tiazolokarboksylowego i sposób ich wytwarzania
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
WO2005027887A2 (en) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Methods and compositions for improving endothelial function
CA2617248C (en) 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US20070208041A1 (en) * 2005-10-13 2007-09-06 Stamler Jonathan S Compositions for the treatment and prevention of heart disease and methods of using same
WO2007062028A2 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
WO2008064015A1 (en) 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America Methods for preserving renal function using xanthine oxidoreductase inhibitors

Also Published As

Publication number Publication date
IT1400310B1 (it) 2013-05-24
IL222926A0 (en) 2012-12-31
TW201206430A (en) 2012-02-16
SG185445A1 (en) 2012-12-28
BR112012028892A2 (pt) 2016-07-26
CA2798707A1 (en) 2011-11-17
CL2012003033A1 (es) 2013-06-21
JP2013526499A (ja) 2013-06-24
WO2011141387A1 (en) 2011-11-17
ITRM20100231A1 (it) 2011-11-11
MX2012013052A (es) 2013-07-03
KR20130079427A (ko) 2013-07-10
AU2011252193A1 (en) 2012-11-29
EP2568981A1 (en) 2013-03-20
CN103025329A (zh) 2013-04-03
US20130116291A1 (en) 2013-05-09
CO6630144A2 (es) 2013-03-01
NZ603397A (en) 2014-03-28
CR20120618A (es) 2014-03-21
ZA201209294B (en) 2013-08-28
MA34232B1 (fr) 2013-05-02
AR081375A1 (es) 2012-08-29
PE20130811A1 (es) 2013-08-08

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201200559A1 (ru) Способы назначения терапии пирфенидоном
EA201290103A1 (ru) Гетероциклические соединения и их использование
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
EA201100119A1 (ru) Химические соединения 251
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201201509A1 (ru) Фармацевтические составы, содержащие пиоглитазон и линаглиптин
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
EA201171414A1 (ru) Ингибиторы белков семейства iap
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
PH12015502706A1 (en) Oral formulation for the treatment of cardiovascular diseases
EA201201529A1 (ru) Комбинация ингибиторов ксантиноксидазы и статинов и ее применение
EA201201528A1 (ru) Комбинация ингибиторов ксантиноксидазы и антагонистов рецепторов ангиотензина-ii и ее применение
BR112013004714A2 (pt) "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز
TR201203085A2 (tr) Sefetamet ve klavulanik asit içeren bileşimler.